title: [Assessment of the clinical efficacy and safety of fulvestrant in heavily pretreated patients with hormone-receptor positive metastatic breast cancer-a single-institution experience].
abstract: Fulvestrant, a pure estrogen receptor antagonist with no known agonist effects, was approved in September 2011 for the treatment of hormone-receptor positive metastatic breast cancer(MBC)in postmenopausal women in Japan. Here, we present a retrospective review of data from 73 heavily pretreated patients who received a high-dose regimen of fulvestrant in our hospital. Patients received a median of 3 endocrine therapies(range: 1-7)prior to the fulvestrant regimen. Partial response was observed in 4 patients, and 10 patients experienced stable disease for more than 6 months(objective response rate: 5.5%; clinical benefit rate: 19.2%). The median time to progression was 2.8 months. Fulvestrant was well tolerated; however, Grade 3 neuropathy at the injection site was observed in 2 patients. Of 12 patients, 3 responded to endocrine therapy following fulvestrant treatment. Our clinical experience indicates that fulvestrant can be administered to patients pretreated with several lines of endocrine therapy, although its efficacy as first- or second-line endocrine therapy has been demonstrated in clinical trial settings.
authors: Dept. of Breast Oncology, Aichi Cancer Center Hospital.
authors: Masaya
authors: M
authors: Hattori
authors: Akiyo
authors: A
authors: Horio
authors: Masataka
authors: M
authors: Sawaki
authors: Naoto
authors: N
authors: Kondo
authors: Takashi
authors: T
authors: Fujita
authors: Aya
authors: A
authors: Ushio
authors: Naomi
authors: N
authors: Gondo
authors: Ai
authors: A
authors: Idota
authors: Mari
authors: M
authors: Ichikawa
authors: Hiroji
authors: H
authors: Iwata
mesh_terms: D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077267:Fulvestrant; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors; D012008:Recurrence
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D000077267:Fulvestrant; D004958:Estradiol